Dennis Ding
Stock Analyst at Jefferies
(0)
# 4774
Out of 5,218 analysts
17
Total ratings
28.57%
Success rate
-22.54%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Inhibikase Therapeut... | Initiates Coverage On: Buy | 8 | 3.41 | 134.6% | 1 | Nov 8, 2024 | |
Assembly Biosciences | Upgrades: Buy | 2 35 | 15.35 | 128.01% | 1 | Sep 20, 2024 | |
Amicus Therapeutics | Initiates Coverage On: Buy | 18 | 9.36 | 92.31% | 1 | Sep 6, 2024 | |
Arbutus Biopharma | Maintains: Strong Buy | 5 7 | 3.48 | 101.15% | 2 | Sep 5, 2024 | |
Recursion Pharmaceut... | Maintains: Hold | 8 6 | 6.94 | -13.54% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 1 | 0.18 | 177.78% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 18 | 0.26 | 6823.08% | 1 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 35 22 | 55.4 | -60.29% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 24 | 24.49 | -2% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 30 | n/a | n/a | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | n/a | n/a | 1 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 195 52 | n/a | n/a | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 10 | 11.83 | -15.47% | 1 | Oct 26, 2021 |